Medistem, Inc., is focused on the development of the Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product. ERCs possess specialized abilities to stimulate new blood vessel growth and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These unique properties have applications for treatment of critical limb ischemia (CLI), congestive heart failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes.
Medistem (OTCMKTS:MEDS), Enters Collaboration with Boston Academic Teaching Hospital to Expand Preclinical Data in Type 1 Diabetes
Medistem, Inc. (OTCMKTS:MEDS), announced today it has entered into collaboration with Reza Abdi, M.D., Transplant Nephrologist at Brigham and Women's Hospital and Assistant Professor of Medicine, Harvard Medical School.
2,809 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 2) (Last 30 Days: 5) (Since Published: 2809)